CN Patent

CN117716034A — 肽标签和编码该肽标签的核酸

Assigned to Stender Therapy Ltd · Expires 2024-03-15 · 2y expired

What this patent protects

本发明提供肽标签和编码该肽标签的核酸。本发明的肽标签可以降低细胞内的蛋白质的聚集性。本发明的肽标签具体而言可以为构成氨基酸序列的氨基酸的5％以上且小于45％为酸性氨基酸且(b)构成氨基酸序列的氨基酸的20％以上为选自由F、P、Y、G、S、Q、N和A组成的组中的氨基酸的肽标签。

USPTO Abstract

本发明提供肽标签和编码该肽标签的核酸。本发明的肽标签可以降低细胞内的蛋白质的聚集性。本发明的肽标签具体而言可以为构成氨基酸序列的氨基酸的5％以上且小于45％为酸性氨基酸且(b)构成氨基酸序列的氨基酸的20％以上为选自由F、P、Y、G、S、Q、N和A组成的组中的氨基酸的肽标签。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: CN117716034A
Jurisdiction: CN
Classification: —
Expires: 2024-03-15
Drug substance claim: No
Drug product claim: No
Assignee: Stender Therapy Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.